ACROBiosystems and Xing Yiang Announce Strategic Collaboration to Accelerate Cell Therapy Drug Development and Commercialization

When the strength of all is pooled, there is nothing that cannot be achieved; when the wisdom of the crowd is applied, there is nothing that cannot be accomplished. On December 4, 2023, Xingyiang (Shanghai) Biotechnology Co., Ltd. ("Xingyiang") and ACROBiosystems Group ("ACROBiosystems") officially signed a strategic cooperation agreement at the Waigaoqiao Free Trade Zone No.1 Life Science Park, where Xingyiang is located. Attending the signing ceremony were Mr. Chen Yiding, Founder, Chairman and CEO of ACROBiosystems; Ms. Zhao Yun, Vice President of Cooperative Development and CEO of bioSeedin; Dr. Huang Xu, Vice President of Sales; Dr. Chen Jinqiu, Vice President of Product Development; Ms. Chen Xiaohong, Pre-sales Technical Lead for East and South China; Ms. Zhang Lulu, Regional Manager for Shanghai; Ms. Ke Ke, Corporate Development Manager; Mr. Luan Die, Technical Manager for the Shanghai region; as well as Dr. Wang Liqun, Founder, Chairman and CEO of Xingyiang; Dr. Zong Hongliang, Vice President of CMC; Dr. Zhang Lei, Vice President of R&D; Dr. Sun Mu, Vice President of Business Development and Strategy; and Ms. Wu Dongfan, BD Manager.

Both parties highly recognize the commercial potential and sustainable value of each other as global strategic partners, and are willing to fully leverage their respective advantages to establish a comprehensive strategic partnership covering multiple business ecosystems worldwide, including but not limited to business cooperation, resource sharing, joint development, commercial licensing, investment and financing.

Mr. Chen Yiding, Chairman and CEO of ACROBiosystems, stated, "We are very pleased to have the opportunity to engage in an in-depth collaboration with Xingyiang Bio, an innovative company in the next-generation cell therapy field. ACROBiosystems is committed to providing innovative products and solutions to overcome challenges throughout the entire biopharmaceutical R&D, production, and clinical process. By partnering with Xingyiang, we will fully leverage our strengths in a rich pipeline of key biological reagents, a sales network and logistics system covering major countries and regions globally, diverse industry resources, and capital strength. We will provide our partners with the most comprehensive support in product and service delivery, co-development of products, licensing, and investment incubation. The management team at Xingyiang has extensive industrial experience in the cell therapy field and a deep understanding of market demands. I believe that our alliance will promote industry innovation and accelerate the development, market entry, and better clinical application of new drugs in the cell therapy sector."

ACROBiosystems will provide a series of solutions for Xingyiang (Shanghai) Biotechnology Co., Ltd. in the research, production, and clinical development of cell therapy drugs, including but not limited to critical biological reagent products and services such as antigen proteins, GMP-grade cytokines, antibodies, magnetic beads, enzymes, cell lines from the catalog and custom development, testing and validation services, as well as related commercial or customized kits.ACROBiosystems will also collaborate with its subsidiary brand bioSeedin, leveraging its resources and network covering nearly 10,000 pharmaceutical enterprise customers globally, a senior global BD team in the industry, and a full-process license-in and license-out trading platform and service system, to help Xingyiang (Shanghai) Biotechnology Co., Ltd. find partners more quickly and accurately, facilitate deal-making, and ensure final implementation.

Dr. Wang Liqun, Chairman and CEO of Xingyiang (Shanghai) Biotechnology Co., Ltd., stated, "This strategic cooperation is based on the shared understanding and mutual willingness to collaborate on the industrialization needs of a new generation of universal cell therapy products. We look forward to the partner value that ACROBiosystems can bring to Xingyiang. We recognize ACROBiosystems' product quality, technical strength, and ability to integrate industry resources beyond just products and technology to provide comprehensive solutions. Both parties will commit to jointly promoting the vision of localized production in China, improving the industry ecosystem, and anticipate more achievements in developing cell therapy products, which can help patients and contribute to human health."

After the strategic signing ceremony, the two parties had an in-depth discussion on cooperation details, especially on product supply and project collaboration related to production.

Introduction to ACROBiosystems (Baipusai)

ACROBiosystems Group (Stock Code: 301080), established in 2010, is a multinational biotechnology company and an industry platform-based cornerstone enterprise providing critical biological reagent products and solutions to the global biopharmaceutical and health industries. It was listed on the Growth Enterprise Market in 2021. ACROBiosystems Group operates globally across Asia, North America, and Europe, with offices, R&D centers, and production bases in more than ten cities in countries such as China, the United States, and Switzerland. To date, it has served over 8,000 customers cumulatively and established long-term, stable partnerships with all of the world’s Top 20 pharmaceutical companies. The group owns several brands.AACROBiosystemsbioSeedin Biothink,Condense Capital, Kentuo Capital, and ACRODiagnostic ACROBiosystems, etc.

ACROBiosystems Group is committed to accelerating the research, development, and market launch of biopharmaceuticals while serving better clinical applications. Through its efforts, the company aims to create value for customers and the entire global industry. By continuously updating technologies, products, and services, ACROBiosystems actively empowers its partners to expedite the development and clinical application of various biopharmaceuticals, including targeted therapies and immunotherapies. Ultimately, the company strives to contribute to the advancement of human health.

Introduction to Xingyiang

Xingyiang (Shanghai) Biotechnology Co., Ltd. focuses on the advanced technology of iPSC-derived CAR-NK, innovating from the two aspects of product and process development. It develops a new generation of universal, mass-producible immune cell products capable of treating solid tumors, filling a global gap. This significantly reduces the production cost of cellular products, increases the coverage of indications, and provides accessible and affordable high-quality cell therapies for cancer patients worldwide, establishing China's leading position.The company has currently obtained 4 software copyright patents, received acceptance for 7 national invention patents, and 2 PCTs.Completed two rounds of financing totaling 98 million US dollars, and within less than three years of establishment, the candidate product is about to launch clinical validation.

>>>Recommended Reading

◆ Good News! ACROBiosystems and Orange Sail Pharmaceuticals Reach Strategic Cooperation to Provide Full-process Solutions, Accelerating Drug R&D and Market Launch

ACROBiosystems

inquiry@acrobiosystems.com

15117918562

(Note: Name + Company)